Vor Biopharma Inc (VOR) USD0.0001

Sell:$2.70Buy:$2.71$1.08 (56.54%)

NASDAQ:0.92%
Market closed | Prices delayed by at least 15 minutes
Sell:$2.70
Buy:$2.71
Change:$1.08 (56.54%)
Market closed | Prices delayed by at least 15 minutes
Sell:$2.70
Buy:$2.71
Change:$1.08 (56.54%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Key people

Jean-Paul Kress
Chairman of the Board, Chief Executive Officer
Daniella Beckman
Independent Director
Erez Kalir
Independent Director
David Charles Lubner
Independent Director
Sven Ante Lundberg
Independent Director
Fouad Namouni
Independent Director
Click to see more

Key facts

  • EPIC
    VOR
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US9290331084
  • Market cap
    $238.67m
  • Employees
    159
  • Shares in issue
    124.96m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.